Journal rankings · indicator year 2002
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Field ranking · 2002
Pharmacology, Toxicology and Pharmaceutics journal rankings 2002
30 ranked journals · Field in Life Sciences
Pharmacology, Toxicology and Pharmaceutics has 30 ranked journals in 2002. The median journal has an OJR of 0.72, below the world average of 1.00, unchanged on 2001; Q1 starts at OJR 1.36. The top three are Pharmacogenetics, Current Drug Metabolism, and Drug Safety.
Ranks and citation indicators: 2002. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 1999–2001, the window the 2002 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields in Pharmacology, Toxicology and Pharmaceutics (4)
Up to Life Sciences30 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2001. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 1999–2001, the window the 2002 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 1999–2001 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2000 to 2002. | Compare |
|---|---|---|---|---|---|---|---|
1PharmacogeneticsLippincott Williams & Wilkins · United Kingdom | 2.59Q1 | 5.58 1.23 up from 2001 | 247 | 2% | — | ||
2Current Drug MetabolismBentham Science Publishers · Netherlands | 2.28Q1 | 2.80 1.99 up from 2001 | 49 | 2% | — | ||
3Drug SafetyAdis, Springer Healthcare · New Zealand | 2.27Q1 | 4.01 0.13 up from 2001 | 251 | 2% | $4,990 | ||
4Critical Reviews in Therapeutic Drug Carrier SystemsBegell House · United States | 2.10Q1 | 2.38 0.01 down from 2001 | 41 | 0% | — | ||
5PharmacogenomicsFuture Medicine · United Kingdom | 1.67Q1 | 3.92 2.29 up from 2001 | 74 | 2% | — | ||
6Drug Metabolism and DispositionAmerican Society for Pharmacology and Experimental Therapeutics · United States | 1.47Q1 | 3.62 1.40 up from 2001 | 460 | 2% | $3,500 | ||
7European Journal of Pharmaceutics and BiopharmaceuticsElsevier BV · Netherlands | 1.41Q1 | 1.98 0.43 up from 2001 | 241 | 2% | $4,210 | ||
8Pharmaceutical ResearchSpringer Science+Business Media · United States | 1.36Q1 | 2.07 0.24 down from 2001 | 807 | 4% | $4,690 | ||
9European Journal of Pharmaceutical SciencesOAElsevier BV · Netherlands | 1.24Q2 | 2.00 0.15 up from 2001 | 393 | 3% | $3,070 | ||
10XenobioticaTaylor & Francis · United Kingdom | 1.12Q2 | 1.99 0.39 up from 2001 | 245 | 7% | — | ||
11Drug metabolism and drug interactionsDe Gruyter · Germany | 1.08Q2 | 2.34 1.70 up from 2001 | 71 | 0% | — | ||
12International Journal of PharmaceuticsElsevier BV · Netherlands | 1.07Q2 | 1.60 0.14 up from 2001 | 1,166 | 2% | $4,650 | ||
13Journal of Analytical ToxicologyOxford University Press · United Kingdom | 1.01Q2 | 1.55 0.01 down from 2001 | 352 | 29% | $4,823 | ||
14Journal of Fluorine ChemistryElsevier BV · Netherlands | 0.88Q2 | 1.13 0.16 up from 2001 | 715 | 0% | $3,660 | ||
15Journal of MicroencapsulationTaylor & Francis · United Kingdom | 0.76Q2 | 1.01 0.01 up from 2001 | 211 | 6% | — | ||
16The Pharmacogenomics JournalSpringer Nature · United Kingdom | 0.68Q3 | 1.33no 2001 value | 60 | 13% | $4,890 | — | |
17Drug DeliveryOATaylor & Francis · United Kingdom | 0.64Q3 | 1.20 0.50 up from 2001 | 91 | 100% | $2,864 | ||
18Pharmaceutical Science & Technology TodayElsevier BV · United Kingdom | 0.61Q3 | 0.80 0.10 down from 2001 | 189 | — | — | ||
19Drug Development and Industrial PharmacyTaylor & Francis · United States | 0.58Q3 | 0.70 0.14 up from 2001 | 472 | 2% | — | ||
20AAPS PharmSciAmerican Association of Pharmaceutical Scientists · United States | 0.50Q3 | 0.99 0.25 down from 2001 | 94 | 94% | — | ||
21Pharmaceutical Development and TechnologyTaylor & Francis · United States | 0.46Q3 | 0.71 0.13 down from 2001 | 212 | 0% | — | ||
22Biopharmaceutics & Drug DispositionWiley · United Kingdom | 0.44Q3 | 0.78 0.10 up from 2001 | 143 | 3% | $3,800 | ||
23European Journal of Drug Metabolism and PharmacokineticsAdis, Springer Healthcare · France | 0.33Q3 | 0.39 0.04 up from 2001 | 147 | 2% | $2,690 | ||
24AAPS PharmSciTechSpringer Science+Business Media · United States | 0.29Q4 | 0.45 0.02 up from 2001 | 101 | 75% | $4,190 | ||
25YAKUGAKU ZASSHIOAPharmaceutical Society of Japan · Japan | 0.24Q4 | 0.48 0.09 down from 2001 | 325 | 95% | — | ||
26Dissolution TechnologiesUnited States | 0.16Q4 | 0.12 0.19 down from 2001 | 44 | 20% | — | ||
27Scientia PharmaceuticaOAÖsterreichische Apotheker-Verlagsgesellschaft m. b. H. · Switzerland | 0.14Q4 | 0.19 0.01 down from 2001 | 83 | 100% | $1,207 | ||
28Journal of Pharmaceutical Marketing & ManagementHaworth Press · United States | 0.13Q4 | 0.17 0.17 up from 2001 | 39 | 0% | — | ||
29Annales de Toxicologie AnalytiqueElsevier BV · France | 0.10Q4 | 0.13 0.10 down from 2001 | 47 | 97% | $3,140 | ||
30Journal of Pharmaceutical InvestigationSpringer Science+Business Media · South Korea | 0.00Q4 | 0.00no change | 97 | 0% | $3,890 |
Subfields of Pharmacology, Toxicology and Pharmaceutics, compared.
Journals
Citations made in 2002. Corpus-wide, 69.2% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
8 additional Pharmacology, Toxicology and Pharmaceutics journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 1999–2001, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2002. Publication window: 1999–2001. How these summaries are calculated
- Ranked journals
- 30
- Window papers (baseline)
- 23,158 Change unavailable from indicator year 1999
- Median OJR
- 0.722 Change unavailable from indicator year 1999
- Rising journals (2025)
- 4Comparison-group list (4)
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 1999–2001 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 23 | 27 | 30 | 32 | 32 | 34 | 37 | 38 | 40 | 43 | 44 | 49 | 54 | 61 | 69 | 71 | 74 | 71 | 73 | 75 | 70 | 72 | 75 | 73 | 72 | 68 | |
| Window papers (baseline) | 20,428 | 21,714 | 23,158 | 25,397 | 26,889 | 29,157 | 31,606 | 34,777 | 38,146 | 41,640 | 45,814 | 49,553 | 53,613 | 56,245 | 59,173 | 59,681 | 59,061 | 56,321 | 53,536 | 51,719 | 51,606 | 54,267 | 56,608 | 57,539 | 56,944 | 58,541 | |
| Median OJR | 0.620 | 0.717 | 0.722 | 0.88 | 0.86 | 0.83 | 0.91 | 1.11 | 0.9471 | 0.97 | 0.949 | 1.03 | 0.9469 | 0.80 | 0.70 | 0.720 | 0.61 | 0.7184 | 0.74 | 0.628 | 0.77 | 0.621 | 0.67 | 0.630 | 0.625 | 0.7176 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 2.7% | 62 journals |
| Retracted papers per 1,000 | Pooled rate: 1.221 per 1,000 | 51 journals |
| Output growth | Median: -1.6% | 60 journals |
| Open access share | Median: 44.5% | 68 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,605 | 32 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 22.2% | 67 journals |
| Review share | Median: 0.4% | 68 journals |
| Articles-only OJR | Median: 0.74 | 68 journals |
| Uncited share | Median: 25.2% | 68 journals |
| Citation concentration | Median: 43.7% | 68 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.